Crain E F, Gershel J C, Kadar A, Kastner T
Department of Pediatrics, Albert Einstein College of Medicine, Bronx, NY.
Pediatr Emerg Care. 1987 Sep;3(3):143-6. doi: 10.1097/00006565-198709000-00001.
The dose-related effects of inhaled 5% metaproterenol solution in asthmatic children between the ages of six and 12 years with acute bronchospasm were evaluated. Tests included FEV1.0, FEF25-75, and PEFR. For entry into the study, subjects were required to have an FEV1.0 or an FEF25-75 less than 80% of the child's predicted normal value based on height and race. Sixty children were randomly assigned in double-blind fashion to receive one of four different doses of 5% metaproterenol inhalant solution: 0.0 ml (placebo), 0.1 ml, 0.2 ml, or 0.3 ml. Drug efficacy was assessed by spirometry using a DeVilbiss Surveyor I spirometer. Spirometry was performed prior to inhalation of the test dose (baseline) and four times after inhalation: immediately after and 15, 30, and 60 minutes after inhalation. Patients in the three treated groups had significantly higher peak post-dose FEV1.0 and FEF25-75 than the placebo group but were not significantly different from one another. There was a significant relationship between dose and incidence of side effects. These results suggest that 0.1 ml (5 mg) of nebulized metaproterenol may provide as much bronchodilatation as higher doses with fewer side effects.
对6至12岁患有急性支气管痉挛的哮喘儿童吸入5%间羟异丙肾上腺素溶液的剂量相关效应进行了评估。测试包括第1秒用力呼气量（FEV1.0）、25%至75%用力呼气流量（FEF25 - 75）和呼气峰值流速（PEFR）。为进入研究，受试者需根据身高和种族，其FEV1.0或FEF25 - 75低于儿童预测正常值的80%。60名儿童以双盲方式随机分配，接受四种不同剂量的5%间羟异丙肾上腺素吸入溶液之一：0.0毫升（安慰剂）、0.1毫升、0.2毫升或0.3毫升。使用德维比斯Surveyor I型肺活量计通过肺量测定法评估药物疗效。在吸入测试剂量前（基线）以及吸入后四次进行肺量测定：吸入后立即以及吸入后15、30和60分钟。三个治疗组的患者给药后FEV1.0和FEF25 - 75的峰值显著高于安慰剂组，但彼此之间无显著差异。剂量与副作用发生率之间存在显著关系。这些结果表明，0.1毫升（5毫克）雾化吸入的间羟异丙肾上腺素可能与更高剂量一样提供同等程度的支气管扩张作用，且副作用更少。
